Predicting Optimal Hypertension Treatment Pathways Using Recurrent Neural Networks.


Journal

International journal of medical informatics
ISSN: 1872-8243
Titre abrégé: Int J Med Inform
Pays: Ireland
ID NLM: 9711057

Informations de publication

Date de publication:
07 2020
Historique:
received: 21 11 2019
revised: 13 03 2020
accepted: 18 03 2020
pubmed: 28 4 2020
medline: 24 10 2020
entrez: 28 4 2020
Statut: ppublish

Résumé

In ambulatory care settings, physicians largely rely on clinical guidelines and guideline-based clinical decision support (CDS) systems to make decisions on hypertension treatment. However, current clinical evidence, which is the knowledge base of clinical guidelines, is insufficient to support definitive optimal treatment. The goal of this study is to test the feasibility of using deep learning predictive models to identify optimal hypertension treatment pathways for individual patients, based on empirical data available from an electronic health record database. This study used data on 245,499 unique patients who were initially diagnosed with essential hypertension and received anti-hypertensive treatment from January 1, 2001 to December 31, 2010 in ambulatory care settings. We used recurrent neural networks (RNN), including long short-term memory (LSTM) and bi-directional LSTM, to create risk-adapted models to predict the probability of reaching the BP control targets associated with different BP treatment regimens. The ratios for the training set, the validation set, and the test set were 6:2:2. The samples for each set were independently randomly drawn from individual years with corresponding proportions. The LSTM models achieved high accuracy when predicting individual probability of reaching BP goals on different treatments: for systolic BP (<140 mmHg), diastolic BP (<90 mmHg), and both systolic BP and diastolic BP (<140/90 mmHg), F1-scores were 0.928, 0.960, and 0.913, respectively. The results demonstrated the potential of using predictive models to select optimal hypertension treatment pathways. Along with clinical guidelines and guideline-based CDS systems, the LSTM models could be used as a powerful decision-support tool to form risk-adapted, personalized strategies for hypertension treatment plans, especially for difficult-to-treat patients.

Sections du résumé

BACKGROUND
In ambulatory care settings, physicians largely rely on clinical guidelines and guideline-based clinical decision support (CDS) systems to make decisions on hypertension treatment. However, current clinical evidence, which is the knowledge base of clinical guidelines, is insufficient to support definitive optimal treatment.
OBJECTIVE
The goal of this study is to test the feasibility of using deep learning predictive models to identify optimal hypertension treatment pathways for individual patients, based on empirical data available from an electronic health record database.
MATERIALS AND METHODS
This study used data on 245,499 unique patients who were initially diagnosed with essential hypertension and received anti-hypertensive treatment from January 1, 2001 to December 31, 2010 in ambulatory care settings. We used recurrent neural networks (RNN), including long short-term memory (LSTM) and bi-directional LSTM, to create risk-adapted models to predict the probability of reaching the BP control targets associated with different BP treatment regimens. The ratios for the training set, the validation set, and the test set were 6:2:2. The samples for each set were independently randomly drawn from individual years with corresponding proportions.
RESULTS
The LSTM models achieved high accuracy when predicting individual probability of reaching BP goals on different treatments: for systolic BP (<140 mmHg), diastolic BP (<90 mmHg), and both systolic BP and diastolic BP (<140/90 mmHg), F1-scores were 0.928, 0.960, and 0.913, respectively.
CONCLUSIONS
The results demonstrated the potential of using predictive models to select optimal hypertension treatment pathways. Along with clinical guidelines and guideline-based CDS systems, the LSTM models could be used as a powerful decision-support tool to form risk-adapted, personalized strategies for hypertension treatment plans, especially for difficult-to-treat patients.

Identifiants

pubmed: 32339929
pii: S1386-5056(19)31343-7
doi: 10.1016/j.ijmedinf.2020.104122
pmc: PMC10490557
mid: NIHMS1926018
pii:
doi:

Substances chimiques

Antihypertensive Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104122

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001067
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest JCF is partially funded by NIH award UL1TR001067 from the National Center for Advancing Translational Sciences of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Références

Int J Med Inform. 2020 Apr;136:104067
pubmed: 31955052
J Thorac Oncol. 2010 Sep;5(9):1315-6
pubmed: 20736804
NCHS Data Brief. 2010 Apr;(36):1-8
pubmed: 20423605
JAMA. 2014 Feb 5;311(5):507-20
pubmed: 24352797
J Gen Intern Med. 2008 Apr;23(4):429-41
pubmed: 18373141
Ann Transl Med. 2018 Jun;6(11):216
pubmed: 30023379
J Am Med Inform Assoc. 2017 Mar 1;24(2):361-370
pubmed: 27521897
Sci Rep. 2018 Feb 21;8(1):3395
pubmed: 29467373
JAMA. 2003 May 21;289(19):2560-72
pubmed: 12748199
Curr Hypertens Rep. 2018 Jul 6;20(9):75
pubmed: 29980865
BMC Med Inform Decis Mak. 2019 Jul 29;19(1):146
pubmed: 31357998
Am J Hypertens. 2015 Jun;28(6):814-22
pubmed: 25421796
Hypertension. 2011 Jun;57(6):1076-80
pubmed: 21502568
Biochem Med (Zagreb). 2012;22(3):276-82
pubmed: 23092060
Circ Res. 2019 Mar 29;124(7):1124-1140
pubmed: 30920917
Perspect Clin Res. 2011 Jul;2(3):109-12
pubmed: 21897887
Am Health Drug Benefits. 2010 Jan;3(1):47-56
pubmed: 25126308
JMLR Workshop Conf Proc. 2016 Aug;56:301-318
pubmed: 28286600
J Am Soc Hypertens. 2016 Oct;10(10):753-754
pubmed: 27660007
Am J Manag Care. 2011 Sep;17(9):626-32
pubmed: 21902448
Hypertension. 2005 Aug;46(2):280-6
pubmed: 15983235
Neural Comput. 1997 Nov 15;9(8):1735-80
pubmed: 9377276
J Am Heart Assoc. 2015 Jan 05;4(1):e001213
pubmed: 25559011
Zhonghua Liu Xing Bing Xue Za Zhi. 2008 Jun;29(6):614-7
pubmed: 19040050
JAMA. 2005 Mar 9;293(10):1223-38
pubmed: 15755945
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
Int J Med Inform. 2019 Dec;132:103986
pubmed: 31629312
PLoS One. 2018 Apr 18;13(4):e0195344
pubmed: 29668729
J Am Coll Cardiol. 2018 May 15;71(19):2176-2198
pubmed: 29146534
Am J Manag Care. 2011 Dec;17(12 Spec No.):SP103-10
pubmed: 22216768
Am Heart J. 2009 Mar;157(3):450-6
pubmed: 19249414
Ann Intern Med. 2006 Aug 1;145(3):165-75
pubmed: 16880458
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248
pubmed: 29146535
Integr Blood Press Control. 2018 Sep 20;11:65-71
pubmed: 30288097
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD001096
pubmed: 19588323
PLoS One. 2015 Jul 10;10(7):e0130140
pubmed: 26161953
PLoS Med. 2010 Mar 23;7(3):e1000248
pubmed: 20351772
Neural Netw. 2005 Jun-Jul;18(5-6):602-10
pubmed: 16112549
BMJ. 2000 Mar 11;320(7236):686-90
pubmed: 10710578
J Intern Med. 2000 Jan;247(1):87-93
pubmed: 10672135
Circ Cardiovasc Qual Outcomes. 2009 May;2(3):170-7
pubmed: 20031834
Circulation. 2014 Nov 4;130(19):1692-9
pubmed: 25332288
N Engl J Med. 2015 Nov 26;373(22):2103-16
pubmed: 26551272

Auteurs

Xiangyang Ye (X)

Department of Biomedical Informatics, The University of Utah, 421 Wakara Way, Suite 140, Salt Lake City, UT, 84108, USA. Electronic address: xiangyang.ye@utah.edu.

Qing T Zeng (QT)

Department of Biomedical Informatics, The University of Utah, 421 Wakara Way, Suite 140, Salt Lake City, UT, 84108, USA; Department of Clinical Research and Leadership, The George Washington University, 2600 Virginia Ave., NW, First Floor, Washington DC, 20037, USA.

Julio C Facelli (JC)

Department of Biomedical Informatics, The University of Utah, 421 Wakara Way, Suite 140, Salt Lake City, UT, 84108, USA.

Diana I Brixner (DI)

Department of Pharmacotherapy, The University of Utah, 30 South 2000 East, Salt Lake City, UT, 84108, USA.

Mike Conway (M)

Department of Biomedical Informatics, The University of Utah, 421 Wakara Way, Suite 140, Salt Lake City, UT, 84108, USA.

Bruce E Bray (BE)

Department of Biomedical Informatics, The University of Utah, 421 Wakara Way, Suite 140, Salt Lake City, UT, 84108, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH